4519 On Other Exchanges
Symbol
Exchange
4519 is not on other exchanges.

chugai pharmaceutical co ltd (4519) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHUGAI PHARMACEUTICAL CO LTD (4519)
\

Related News

No related news articles were found.

chugai pharmaceutical co ltd (4519) Related Businessweek News

No Related Businessweek News Found

chugai pharmaceutical co ltd (4519) Details

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research and development, manufacture, marketing, and distribution of prescription medicines in Japan, Switzerland, and internationally. The company's products for oncology include Avastin, Herceptin, Rituxan, Xeloda, Tarceva, Perjeta, Alecensa, Neutrogin, Kadcyla, Zelboraf, Aloxi, and Akynzeo; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, Bonviva, and Alfarol; renal diseases consist of Mircera, Oxarol, and Epogin; and transplant, immunology, infectious, and other diseases comprise Tamiflu, CellCept, Copegus, Pegasys, and Sigmart. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

7,245 Employees
Last Reported Date: 03/23/17
Founded in 1925

chugai pharmaceutical co ltd (4519) Top Compensated Officers

Chairman & CEO
Total Annual Compensation: ¥267.0M
President, COO & Representative Director
Total Annual Compensation: ¥93.0M
Deputy Chairman
Total Annual Compensation: ¥83.0M
Compensation as of Fiscal Year 2016.
chugai pharmaceutical co ltd
Chugai Pharmaceutical Co., Ltd.'s Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study

Chugai Pharmaceutical Co., Ltd. announced that the primary endpoint has been met for the global phase lll HAVEN 3 (NCT02847637) study evaluating emicizumab (ACE910) subcutaneous injection, once a week and once every two weeks, in patients with hemophilia A (12 years of age or older) without inhibitors to factor Vlll. A statistically significant reduction in the number of bleeds was confirmed in patients treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. The study also met a secondary endpoint that once-weekly emicizumab prophylaxis was superior to factor VIII prophylaxis, as demonstrated by a statistically significant and clinically meaningful reduction in treated bleeds in an intra-patient comparison of patients receiving emicizumab prophylaxis compared to their prior factor VIII prophylaxis. The most common adverse events with emicizumab were injection site reactions, consistent with prior studies. No thrombotic events occurred in this study. Further details will be presented at a future medical meeting.

Chugai Pharmaceutical Co., Ltd. Receives the Regulatory Approval from FDA for Hemophilia A with Inhibitors

Chugai Pharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration has approved the bispecific antibody emicizumab for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors. This represents the first regulatory approval for HEMLIBRA® around the world. The US Biologics License Application (BLA) was submitted by Genentech, a member of Roche Group. This regulatory approval is based on the data from two clinical studies, the results of HAVEN 1 study (NCT02622321) and the interim analysis of HAVEN 2 study (NCT02795767) in patients with hemophilia A with factor VIII inhibitors. HAVEN 1 included adult and adolescent patients and HAVEN 2 included pediatric patients, and were both conducted under a collaboration between Chugai, Roche and Genentech. In the HAVEN 1 study, adults and adolescents with hemophilia A with inhibitors who received HEMLIBRA prophylaxis (n=35) had a statistically significant and clinically meaningful 87%.

Chugai Pharmaceutical Co., Ltd. and TAIYO HOLDINGS CO., LTD. Enter Agreement to Transfer Marketing and Manufacturing Rights

Chugai Pharmaceutical Co., Ltd. and TAIYO HOLDINGS CO., LTD. announced that they have entered into an agreement, under which Chugai and F. Hoffmann-La Roche, Ltd. will transfer the marketing authorizations, including marketing and manufacturing rights, of 13 long-term listed products manufactured and marketed in Japan by Chugai to TAIYO Pharma Co., Ltd. Chugai aims to contribute to patients and the medical community through the creation of innovative medical products and services based on its business philosophy, Innovation all for the patients. The decision to transfer these long-term listed products was taken to reinforce Chugai's focus on creating innovation, supporting the goal of ensuring sustainable growth by optimizing investment in business segments and products with potential to enhance the company's competitive advantage. The 13 products covered by the agreement will continue to be marketed under the Chugai brand to ensure uninterrupted supply during the handover period. The marketing and manufacturing rights will be transferred to Taiyo Pharma on a step-by-step basis, starting from April 2018. Taiyo Holdings, Taiyo Pharma, and Chugai will cooperate closely to achieve a smooth transfer of marketing authorization and marketing activities regarding the Products. Until completion of the transfer, Taiyo Pharma and Chugai will work together and engage in activities aimed at the provision of information suitable for the treatment of diseases, and the promotion of proper use.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4519 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4519.
View Industry Companies
 

Industry Analysis

4519

Industry Average

Valuation 4519 Industry Range
Price/Earnings 45.9x
Price/Sales 6.0x
Price/Book 4.6x
Price/Cash Flow 47.0x
TEV/Sales 5.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHUGAI PHARMACEUTICAL CO LTD, please visit www.chugai-pharm.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.